We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Rapid Detection of Sepsis-Causing Pathogens

By HospiMedica staff writers
Posted on 13 Mar 2006
A new reliable test for diagnosis and identification of 25 sepsis-causing pathogens has been launched in the United Kingdom. More...
The polymerase chain reaction (PCR) based-test can detect and identify both bacterial and fungal sepsis pathogens in less than six hours.

More than 23,000 UK patients develop severe sepsis each year with a resulting mortality greater than 10,000. This is the equivalent of at least 27 deaths each day. Traditional blood-culture methods can take up to two to five days to diagnose sepsis and even then there is a positive test rate of less than 20% for patients with sepsis. The LightCycler SeptiFast test of Roche Diagnostics (Basel, Switzerlan), provides rapid, reliable results, saving valuable time. Targeted therapy using the correct antibiotic can begin only after pathogens are correctly identified. The ability of the test to detect fungal pathogens is an enormous breakthrough--fungal pathogens are almost impossible to detect using blood cultures, and can take up to eight days to diagnose--accounting for a substantial proportion of fatalities.

The LightCycler SeptiFast test can detect several pathogens simultaneously from just one blood sample. Three milliliters of whole blood are sufficient, even when the sample contains only minute quantities of pathogen DNA. The test can even be used to identify bacteria that have already been treated with antibiotics and therefore would not be detectable by traditional culture methods. The test works on the basis of the PCR. Repeatedly specific sequences are copied from the genetic material of the pathogen (DNA) so that even small initial quantities can be clearly identified. The MGrade quality of the reagents ensures that there is no contamination with microbial genetic material, resulting in reliable results. MGrade is a brand name for a manufacturing process developed by Roche to produce DNA-free disposable products.



Related Links:
Roche

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Ultrasound System
FUTUS LE
PACS Workstation
PaxeraView PRO
Infant Incubator
OKM 801
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.